CeriBell, Inc. CBLL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +21.20%
- 1 year
- +134.81%
- Open
- 27.48
- Prev close
- 27.82
- Mkt cap
- 1.02B
- Vol
- 582.65K
- Avg vol
- 428.69K
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.01
- High
- 27.61
- Forward P/E
- -16.48
- Beta
- 0.93
- Short ratio
- 5.05
- Inst. own
- 90.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 24.88
- 200-d avg
- 20.76
- 1y target
- 28.57
News
3 days ago globenewswire.com
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with…
-
4 weeks ago benzinga.com
TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $33.
2 months ago benzinga.com
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC…
-
2 months ago benzinga.com
BTIG Maintains Buy on CeriBell, Raises Price Target to $30
BTIG analyst Marie Thibault maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $28 to $30.
-
2 months ago benzinga.com
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $25 to $26.
-
2 months ago benzinga.com
CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.000 million-$117.000 million vs $113.979 million estimate.
-
2 months ago benzinga.com
CeriBell Announces FDA 510(k) Clearance For Two New AI Algorithm Enhancements Integrated Directly Into Existing Cloud-Based Neurology Portal: Epileptiform Abnormality Detection And Artifact Reduction
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
-
3 months ago benzinga.com
CeriBell Says U.S. CMS Grants New Technology Add-On Payment For Up To $2,171 Per Eligible Medicare Patient Case Utilizing Ceribell Delirium Monitor System
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today
-
4 months ago benzinga.com
CeriBell Highlights Publication Of New Research Paper, 'Point-Of-Care EEG Artificial Intelligence Measure Of Seizure Burden Associates With Clinical Outcome At Discharge'
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a…
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on CeriBell, Lowers Price Target to $25
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $28 to $25.
-
5 months ago benzinga.com
CeriBell Raises FY2026 Sales Guidance from $111.000M-$115.000M to $112.000M-$116.000M vs $113.138M Est
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.000 million-$116.000 million vs $113.138 million estimate.
-
5 months ago benzinga.com
CeriBell Q1 EPS $(0.52) Misses $(0.39) Estimate, Sales $26.494M Beat $26.088M Estimate
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 44.44 percent decrease over losses of $(0.36)…
-
8 months ago benzinga.com
CeriBell Q4 EPS $(0.36) Beats $(0.41) Estimate, Sales $24.784M Beat $23.942M Estimate
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.41) by 12.62 percent. This is a 10 percent increase over losses of $(0.40) per…
-
8 months ago benzinga.com
Earnings Scheduled For February 24, 2026
Earnings Scheduled For February 24, 2026
9 months ago benzinga.com
Forecasting The Future: 5 Analyst Projections For CeriBell
Forecasting The Future: 5 Analyst Projections For CeriBell
-
10 months ago benzinga.com
Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $30
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price target from $29 to $30.
10 months ago benzinga.com
Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday
Academy Sports and Outdoors, Tronox, STAAR Surgical And Other Big Stocks Moving Higher On Tuesday
-
11 months ago benzinga.com
CeriBell's Clarity Algorithm Gets FDA's Clearance To Detect Electrographic Seizures In Newborns Pre-Term, Older
CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that…
-
12 months ago benzinga.com
JP Morgan Maintains Overweight on CeriBell, Lowers Price Target to $17
JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the price target from $21 to $17.
-
12 months ago benzinga.com
TD Cowen Maintains Buy on CeriBell, Lowers Price Target to $20
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price target from $36 to $20.
-
12 months ago benzinga.com
CeriBell Raises FY2025 Sales Guidance from $85.000M-$88.000M to $87.000M-$89.000M vs $86.940M Est
2025 Financial OutlookCeribell is raising its revenue guidance for the full year 2025 to a range of $87 million to $89 million, representing growth of approximately 33% to 36% over the company's…
-
12 months ago benzinga.com
CeriBell Q3 EPS $(0.37) Beats $(0.41) Estimate, Sales $22.589M Beat $21.779M Estimate
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 10.41 percent. This is a 80 percent increase over losses of $(1.85) per…
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
1 year ago benzinga.com
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
-
1 year ago benzinga.com
Earnings Scheduled For February 25, 2025
Earnings Scheduled For February 25, 2025
1 year ago benzinga.com
Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.
-
1 year ago benzinga.com
Earnings Scheduled For November 12, 2024
Earnings Scheduled For November 12, 2024